Get started
Author

Tetsuro Oishi

Observed names: Oishi, Tetsuro, T OISHI, T Oishi, T. OISHI, T. Oishi, TETSURO OISHI, Tetsuro OISHI
ORCID: 0000-0001-9374-0101
Observed ORCID: 0000-0001-9374-0101
OpenAlex ID: A5008679839
Whole-genome sequencing revealed novel prognostic biomarkers and promising targets for therapy of ovarian clear cell carcinoma
2017 · Hiroaki Itamochi, Tetsuro Oishi, et al. · British Journal of Cancer · 116
PDF
Significance of histologic pattern of carcinoma and sarcoma components on survival outcomes of uterine carcinosarcoma
2016 · K. Matsuo, Y. Takazawa, et al. · Annals of Oncology · 114
PDF
Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial
2019 · Ignace Vergote, Giovanni Scambia, et al. · The Lancet Oncology · 94
PDF
Combination chemotherapy of oxaliplatin and 5‐fluorouracil may be an effective regimen for mucinous adenocarcinoma of the ovary: A potential treatment strategy
2008 · Seiya Sato, Hiroaki Itamochi, et al. · Cancer Science · 81
Chemosensitivity and p53–Bax pathway-mediated apoptosis in patients with uterine cervical cancer
2003 · H. Sultana, J. Kigawa, et al. · Annals of Oncology · 61
PTEN-positive and phosphorylated-Akt-negative expression is a predictor of survival for patients with advanced endometrial carcinoma
2005 · Kazunori Uegaki, Yasunobu Kanamori, et al. · Oncology Reports · 58
Serum Vascular Endothelial Growth Factor-A as a Prognostic Biomarker for Epithelial Ovarian Cancer
2017 · Hiroaki Komatsu, Tetsuro Oishi, et al. · International Journal of Gynecological Cancer · 57
Incidence and risk factors for lower limb lymphedema after gynecologic cancer surgery with initiation of periodic complex decongestive physiotherapy
2014 · Imari Deura, Muneaki Shimada, et al. · International Journal of Clinical Oncology · 56
Glutathione concentration may be a useful predictor of response to second-line chemotherapy in patients with ovarian cancer
1998 · Junzo Kigawa, Yukihisa Minagawa, et al. · Cancer · 56
PDF
Expression of the c‐myc gene as a predictor of chemotherapy response and a prognostic factor in patients with ovarian cancer
2004 · Takahiro Iba, Junzo Kigawa, et al. · Cancer Science · 53
PDF
Expression of hypoxia-inducible factor 1a gene affects the outcome in patients with ovarian cancer
2007 · R. SHIMOGAI, J. KIGAWA, et al. · International Journal of Gynecological Cancer · 46
The PI3K/mTOR dual inhibitor NVP-BEZ235 reduces the growth of ovarian clear cell carcinoma
2014 · TETSURO OISHI, HIROAKI ITAMOCHI, et al. · Oncology Reports · 45
PDF
Checkpoint Kinase Inhibitor AZD7762 Overcomes Cisplatin Resistance in Clear Cell Carcinoma of the Ovary
2013 · Hiroaki Itamochi, Mayumi Nishimura, et al. · International Journal of Gynecological Cancer · 44
Loss of ARID1A expression is associated with poor prognosis in patients with stage I/II clear cell carcinoma of the ovary
2015 · Hiroaki Itamochi, Nao Oumi, et al. · International Journal of Clinical Oncology · 42
Galectin-3 may contribute to Cisplatin resistance in clear cell carcinoma of the ovary
2007 · T. Oishi, H. Itamochi, et al. · International Journal of Gynecological Cancer · 40
Efficacy and safety of standard of care with/without bevacizumab for platinum‐resistant ovarian/fallopian tube/peritoneal cancer previously treated with bevacizumab: The Japanese Gynecologic Oncology Group study JGOG3023
2021 · Tadahiro Shoji, Takayuki Enomoto, et al. · Cancer Science · 38
lncRNA UCA1-Mediated Cdc42 Signaling Promotes Oncolytic Vaccinia Virus Cell-to-Cell Spread in Ovarian Cancer
2019 · Kosuke Horita, Hajime Kurosaki, et al. · Molecular Therapy — Oncolytics · 37
PDF
Genetic diagnosis for chemosensitivity with drug-resistance genes in epithelial ovarian cancer
2006 · J. Naniwa, J. Kigawa, et al. · International Journal of Gynecological Cancer · 33
MEK1/2 Inhibitor Selumetinib (AZD6244) Inhibits Growth of Ovarian Clear Cell Carcinoma in a PEA-15–Dependent Manner in a Mouse Xenograft Model
2011 · Chandra Bartholomeusz, Tetsuro Oishi, et al. · Molecular Cancer Therapeutics · 28
Inhibiting the mTOR Pathway Synergistically Enhances Cytotoxicity in Ovarian Cancer Cells Induced by Etoposide through Upregulation of c-Jun
2011 · Hiroaki Itamochi, Tetsuro Oishi, et al. · Clinical Cancer Research · 28
A newly developed adenovirus-mediated transfer of a wild-type p53 gene increases sensitivity to cis-diamminedichloroplatinum (II) in p53-deleted ovarian cancer cells
1998 · Y Kanamori, J Kigawa, et al. · European Journal of Cancer · 28
Alteration of Telomerase Activity Associated With Development and Extension of Epithelial Ovarian Cancer
1998 · TETSURO OISHI, JUNZO KIGAWA, et al. · Obstetrics and Gynecology · 28
Serum vascular endothelial growth factor A and vascular endothelial growth factor receptor 2 as prognostic biomarkers for uterine cervical cancer
2019 · Mayumi Sawada, Tetsuro Oishi, et al. · International Journal of Clinical Oncology · 26
Recurrence, death, and secondary malignancy after ovarian conservation for young women with early-stage low-grade endometrial cancer
2019 · Koji Matsuo, James C. Cripe, et al. · Gynecologic Oncology · 24
Adenovirus type 5 E1A gene therapy for ovarian clear cell carcinoma: a potential treatment strategy
2007 · Hiroaki Itamochi, Junzo Kigawa, et al. · Molecular Cancer Therapeutics · 24
Works count: 110
Citation count: 1,817
H-index: 24
I10-index: 51
Year
Topic
Type